14 funding opportunities found in this category. Change the order of results:
Lowest Award to Highest
Highest Award to Lowest
Muscular Dystrophy Association Research Grants Programs
MDA supports research aimed at developing treatments for the muscular dystrophies and related diseases of the neuromuscular system. These are the muscular dystrophies (among which are Duchenne and Becker); motor neuron diseases (including ALS and SMA); the peripheral nerve disorders (CMT and Friedreich's ataxia); inflammatory myopathies; disorders of the neuromuscular junction; metabolic diseases of muscle as well as other myopathies.
To be eligible to apply for an MDA research grant, an applicant must:
Hold a Doctor of Medicine (M.D.), Doctor of Philosophy (Ph.D.), Doctor of Science (D.Sc.) or equivalent degree (i.e. D.O.);
Be a professional or faculty member (Professor, Associate Professor or Assistant Professor) at an appropriate educational, medical or research institution;
Be qualified to conduct and mentor a program of original research within his or her own laboratory;
Assume both administrative and financial responsibility for the grant; and
Have access to institutional resources necessary to conduct the proposed research project.
Proposals from applicants outside the United States will be considered for projects of highest priority to MDA and when, in addition to the applicant's having met the requirements noted above, the applicant's country of residence may not have adequate sources of financial support for biomedical research.
NOTE: To apply for a Research Grant, you must be an independent investigator, i.e., not a trainee, not a post-doctoral fellow, not a research assistant, not a research associate and not under the supervision of another person (Principal Investigator/Independent Investigator) who is directing the research.
MDA will consider an application for a research development grant from a candidate who may be a member of a research team in the laboratory of an independent investigator (Principal Investigator) under whose guidance the applicant will be given flexibility to conduct a neuromuscular disease research project.
To be eligible for a Development Grant, an applicant must:
Be a member of a research team at an appropriate institution;
Be qualified to conduct a program of original research under the supervision of a Principal Investigator;
Have an acceptable research plan for a specific disease in MDA's program;
Have access to institutional resources necessary to conduct the proposed research project;
Have a minimum of eighteen (18) months of post-degree research laboratory training at the time of application;
Be no more than 60 months from receiving their most recent advanced degree (e.g. PhD, MD or equivalent); and
Not have been funded under the Development Grant program in the past.
Awards are for either one, two or three years for all grant types.
Funding levels for primary Research Grants are unlimited. Development grants are a maximum of $60,000 per year. Overhead is limited to a maximum of 10% percent of direct costs to be included in the total amount of the grant request.
A pre-proposal form must be submitted through proposalCENTRAL to formally request an application for an MDA research grant. Requests for applications can be submitted anytime prior to the applicable deadline date.
Applications are not open to institutions for general distribution.
ONLY TWO GRANT REVIEW ROUNDS ARE HELD EACH YEAR.
ONLY ONE "LETTER OF INTENT" IS PERMITTED PER GRANT REVIEW ROUND.
Letter of Intent: December 15
Letter of Intent: June 15
Muscular Dystrophy Association
Grants Manager - Research Department
3300 E. Sunrise Drive
Tucson, AZ 85718
(520) 529-5454 (fax)
Friedreich's Ataxia Research Alliance General Research Grant
FARA accepts LOIs from qualified investigators for projects that target FARA’s research priorities twice per year (due February 1 and July 15).
For those invited to submit a full application, the deadlines for submission are April 1 and September 15, respectively.
On the Main Grant Page, put “General Research” in the “Grant Type” field.
The applicant may request a budget of up to $150,000 per year for one or two years.
General Research Grant Subtype:
Postdoctoral Trainees and Ph.D. Students
Salaries for all those contributing to the research project (PI, postdocs, graduate students, research associates, etc.) can be requested under personnel costs in the budget of a General Research Grant application.
Additionally, FARA has an application subtype specifically for PIs requesting only salary (plus applicable benefits) to support postdoctoral trainees and Ph.D. students in their laboratory. The PI is encouraged to involve the trainee/student in the preparation of the research plan to be submitted with the application. The name and CV of the postdoctoral trainee or Ph.D. student must be included in the application.
The guidelines for General Research Grants should be followed, but the only allowable budget item is salary for the postdoctoral trainee or Ph.D. student (plus applicable benefits and tuition support) and the requested amount must not exceed the appropriate NIH stipend level.
FRAXA Research Foundation Grants & Postdoctoral Fellowships for Studies Aimed at Fragile X Treatment
FRAXA aims to accelerate research aimed at finding a specific treatment for fragile X syndrome. Our goal is to bring practical treatment into current medical practice as quickly as possible; therefore, preference will be given to research projects that have a clear practical application and the results of which will be shared in a timely fashion. The next application deadline is February 1, 2014.
FRAXA offers grants in two categories:
Program Grants are intended for only the most translationally relevant proposals; basic science proposals will be streamlined out without review.
Applicants with a more basic approach should consider the Postdoctoral Fellowship program, though these grants are still awarded with weight given to therapeutic potential.
-- $45,000 per year for 2 years (for salary, fringe benefits, & consumable costs)
-- Fixed amount and duration
-- Approximately 8 total fellowships available for 2014, depending on available funds
-- Applicants must be full time and have MD, PhD, or MD/PhD
-- Previous grad/postdoc FRAXA grantees are not eligible (previous PI is OK)
-- Limit of one application per lab group (current grantees are not eligible)
-- PIs must demonstrate adequate overall funding to pursue this project; no supplements will be given for supplies or animal care
-- Grants are non-transferable (only good for specified postdoc, PI, and institution)
FRAXA will offer a limited number of postdoctoral fellowships this year at a fixed rate of $45,000 per year. Successful applicants for these grants will likely be working in established labs with secure overall funding, which have funding for supplies and any required animal handling costs. If the applicant proposes to work with a particular fragile X model (KO mouse, drosophila, human neural stem cells, etc.) s/he should demonstrate that this model system has already been established in-house.
-- No limit to structure of grant (can fund PI, postdoc, grad student, technician, supplies, etc.) or timeframe (though all grants over one year still need yearly renewal)
-- Amount up to $100,000 per year (but please remember that applications are ranked based on relative value, so smaller requests have an advantage!)
-- Grants are given based on innovation and translational relevance: clinical trials are our highest priority, followed by preclinical research (i.e. rescue of animal models) and then translational research
-- Any application with low translational relevance will be streamlined out without review; FRAXA is not able to fund basic science applications in this program
FRAXA invites investigator-initiated research applications for innovative pilot studies aimed at developing and characterizing new therapeutic approaches for the treatment and ultimate cure of fragile X syndrome. These are flexible grants, but we expect that this program will be much more competitive than in the past, since fewer grants will be awarded. Successful applicants will be pursuing advanced translational, preclinical, and clinical research in fragile X.
FRAXA Research Foundation
10 Prince Place, Suite 203
Newburyport, MA 01950
Jane & Henry Bukaty Skin Care Fund
FIRST realizes that the fight against ichthyosis is not only medical, but also financial. As families of affected individuals maintain their daily routine of treatments, it can be complicated by the ongoing costs of medical supplies and other comforting aids and procedures.
Thanks to the generosity of a donor, FIRST has established the Jane & Henry Bukaty Skin Care Fund to help alleviate some of the financial burden that may be facing our members. Here’s your opportunity to apply for some financial assistance for ichthyosis treatment. Since the fund is limited, the following criteria must be met by the applicant in order to be eligible for a grant.
The applicant must be a registered in our database and is required to submit an application indicating his/her need for funding. The application requests the specific product/treatment/cooling device for which funds are needed and also requests a demonstration of the financial need for this product/treatment/cooling device.
Awards will not exceed $200.00 and will be awarded two times per year as determined by the Review Committee. Applicants will be eligible to receive one award every two years.
Applications can be downloaded from the foundation website and emailed to the national office or mailed to the attention of:
Jane & Henry Bukaty Skin Care Fund
Foundation for Ichthyosis & Related Skin Types, Inc.®
2616 N. Broad Street
Colmar, PA 18915
The next cycle of funds awarded will take place in February 2014. The deadline for submitting an application is January 31, 2014.
Request for Proposals 2014: Foundation for Ichthyosis & Related Skin Types, Inc.
The Foundation for Ichthyosis & Related Skin Types, Inc. announces the 2013 research grant program to encourage and support investigation into the causes, treatments, and potential cures for ichthyosis. Letters of Intent will be accepted for detailed investigations.
Schedule for Applications:
Letter of Intent deadline for FY 2014 is February 20, 2014.
The application deadline for FY 2014 is March 28, 2014.
2014 award announcements will be made on June 30, 2014.
Funds available September 1, 2014.
Complete the application form and return to the Moureen at the FIRST office via email. Please include any relevant attachments.
Electronic submissions are preferred. All forms are text interactive.
Jean R. Pickford, Executive Director
Moureen Wenik, Research Coordinator
Foundation for Ichthyosis & Related Skin Types
2616 N. Broad Street
Colmar, PA 18915
FSH Society Research Grants and Fellowships
We are the world's largest and most progressive grassroots network of facioscapulohumeral muscular dystrophy (FSHD) patients, their families and research activists. The FSH Society harnesses the power and insight of a patient-driven model, as it was founded on a promise between two research scientists with FSHD never to let the disease be forgotten or neglected. We are a cause without borders.
FSH Society research and fellowship grant awards provide vital start-up funding for investigators in FSHD and research projects on FSHD. The research milestones and insights gained are demonstrably significant.
The fellowship program allows innovative and entrepreneurial research to develop and ultimately to be able to attract funding from large funding sources such as the US National Institutes of Health (NIH). The FSH Society meets an important need in funding and developing new ideas and supporting new investigators in FSHD research by giving them the funds needed to develop data and to carry their ideas to the next stage of development. Without the FSH Society research and fellowships program, many key initiatives in FSHD research might never have had the chance to begin. Well over 300 peer-reviewed papers have been published by FSH Society-funded researchers.
Since 1998, the FSH Society has transformed FSHD research. The field is on the verge of significant breakthroughs. It is essential to fund new ideas and support new investigators and new lines of investigation when tackling a disease as complex as FSHD.
Deadlines for receipt of grant, research fellowship and postdoctoral fellowship applications are February 28/29 and August 31 of each year.
Cornelia de Lange Syndrome Foundation Research Grants
The CdLS Foundation has a vision and researchers have the determination to find treatments to help individuals with CdLS overcome many of the challenges they face.
Previous Foundation grants have supported research on a range of topics, including dental anesthesia, behavior, aging, parental stress, thrombocytopenia, cell-based studies, and animal models.
$20,000 in funding is available annually. Application's are due by April 15 of each year.
For questions, call 800-753-2357.
Call for Applications: Clinical Trials in Thalassemia Cell and Gene Therapy Grant Award
The purpose of this initiative is to speed the application of recent translational advances in gene therapy to clinical trials. The Foundation recognizes that there are many key areas worthy of support in the search for a cure for thalassemia with cell therapy and gene therapy. While several funding mechanisms are available for a range of studies on vector development, proof of concept studies in animal models, and transplantation, there remains a funding gap for launching human trials. Both phase I (safety) and phase II (efficacy) trials are eligible for support. Funding and candidate eligibility: Total funding of up to $60,000 per year will be available (including indirect costs of 8%). With satisfactory evidence of progress the grant may be renewed for a second year. The research may not be conducted at a for-profit laboratory. Because the purpose of the support is to facilitate launch of clinical trials, eligible studies proposed for this RFA must be accompanied by a realistic timeline of progress to human trials. The Foundation recognizes that this timeline can be long. Applicants should state explicitly the status of their proposed trials, for example whether the trial has been approved by the recombinant DNA Advisory Committee (RAC), or Food and Drug Administration (or equivalent processes at non-US sites), or whether review meetings at regulatory agencies have been scheduled. Awards will be announced in June 2014.
The completed application is due Monday February 3, 2014.